Original title: Popular drugs lie guns?
Wang Sicong "tears" Yiling Pharmaceuticals by hand, calling on the regulatory authorities to investigate!
The company responded aggressively, what happened?
Author: Yun Zhongyue
Yesterday, the big V Wang Sicong, who has more than 40 million Weibo fans, was on the hot search again.
At 13:08 on April 14, Wang Sicong forwarded a message about Lianhua Qingwen Capsules on Weibo, saying that the regulatory authorities should strictly investigate Yiling Pharmaceutical.
Yiling Pharmaceutical also responded quickly: Regarding the news on Weibo, please point out the specific problem and source.
The company also stated that "you cannot ask questions at will because of the three words 'Wang Sicong'."
It is worth mentioning that, as the manufacturer of Lianhua Qingwen Capsules, the share price of Yiling Pharmaceutical has performed brilliantly in the A-share market, rising 104% this year.
Wang Sicong said that the regulatory authorities should strictly investigate Yiling Pharmaceutical, and the company responded!
At 13:08 on April 14, Wang Sicong forwarded a message about Lianhua Qingwen Capsules on Weibo, saying that the regulatory authorities should strictly investigate Yiling Pharmaceutical.
This remark quickly fermented on the Internet.
In response to the remarks on the Internet, Yiling Pharmaceutical quickly responded positively: "Regarding the news on Weibo, please point out the specific problem and source, and we will answer the specific content. From clinical trials to specific experiments We have complete evidence and report disclosure from the data, to being included in the new coronary pneumonia diagnosis and treatment plan, including the indications and instructions. We cannot ask questions at will because of the three words 'Wang Sicong'. For some remarks on the Internet, listen to Just listen, investors, please screen."
About an hour later, Wang Sicong edited the Weibo again, deleting the words that the regulatory authorities should strictly investigate Yiling Pharmaceutical.
Lianhua Qingwen shines brightly, Yiling Pharmaceutical soars by 104% during the year
Since the outbreak of the new crown epidemic, Lianhua Qingwen has shined brightly as a new crown drug.
On April 14, the stock price of Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen Capsules and an A-share listed company, also closed at the daily limit, with a turnover rate of 10.51% throughout the day and a turnover of 5.591 billion yuan.
Since the beginning of this year, Yiling Pharmaceutical's share price has risen by 104.03%, and its latest market value is 66.8 billion yuan.
After the market on April 14, the data of the Dragon Tiger List shows that the first five buying seats in the business department have a total net purchase of 579 million yuan, and the top five selling business departments have a total net sales of 418 million yuan. All the institutions on the Dragon Tiger list that day The total net purchase was 207 million yuan.
It is worth mentioning that the seats of institutions fled yesterday, and there were 3 special seats for institutions that showed up that day, namely selling two, selling three, and selling four, with a total net sales of 139 million yuan.
Recently, the epidemic situation in Shanghai and other places has been on the rise, and Lianhua Qingwen has become an epidemic prevention material for many residents as a recommended drug for the new crown.
On March 31, the WHO website published the Report of the WHO Expert Evaluation Meeting on the Treatment of New Coronary Pneumonia with Traditional Chinese Medicine, which clearly affirmed the safety and effectiveness of traditional Chinese medicine in the treatment of new coronary pneumonia, and encouraged WHO member states to consider Chinese traditional Chinese and Western medicine. Combined model (integrated medicine model).
At the press conference on epidemic prevention and control in Shanghai held on April 5, Fang Min, president of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and head of the TCM epidemic prevention and control base, said that traditional Chinese medicine has played an active role in the prevention and control of the new crown epidemic. In Shanghai, the utilization rate of traditional Chinese medicine has remained stable at more than 98% for positive infections, and traditional Chinese medicine anti-epidemic prescriptions are very popular among patients.
According to a recent research report by Sinolink Securities, Lianhua Qingwen is a recommended drug for the new crown.
Since the outbreak of the epidemic in 2020, Lianhua Qingwen, as one of the "three medicines and three prescriptions", has been included in the fourth to ninth editions of the new crown diagnosis and treatment plan, and is recommended for observation period, mild and ordinary patients with new crowns.
Guosheng Securities believes that Yiling Pharmaceutical is one of the few companies in China that started from the inheritance and innovation of traditional Chinese medicine theory, transformed it into the research and development of new patented Chinese medicine drugs, and achieved success.
In recent years, substantive documents on supporting the innovation of traditional Chinese medicine have been successively issued. In 2021, 12 new drugs of traditional Chinese medicine have been approved, and the number has reached a new high in recent years.
Guosheng Securities also stated that Lianhua Qingwen has become a national product, driven by both influenza and the new crown.
Since its launch, Lianhua Qingwen has proved its outstanding role in diseases such as influenza A, avian influenza, influenza B, and new coronary pneumonia through a number of high-quality clinical experimental studies, and has obtained more than 20 national-level treatment programs. 's recommendation.
In the field of new crowns, Lianhua Qingwen has proved its role in the treatment and prevention of new crowns through clinical trials. The results were published in the authoritative international journals "Phytomedicine" and "Evidence-based Complementary and Alternative Medicine".
Yiling Pharmaceutical’s Lianhua Qingwen’s revenue in 2020 will exceed 4 billion, and its market share will increase from 2.44% to 9.86% in 2017-2020, making it the No. 1 brand of Chinese patent medicines for colds in the retail market; due to restrictions on drug purchases in 2021, It is expected that the revenue will remain at 3.5-4 billion. In the future, Lianhua Qingwen is expected to recover double-digit growth with the help of influenza and the new crown, and there is a possibility of exceeding expectations.
In the current round of Shanghai's new crown epidemic, Yiling Pharmaceutical also donated materials to Shanghai.
On the evening of April 8, Yiling Pharmaceutical announced: "In order to fully support Shanghai's new crown virus epidemic prevention and control work, and earnestly fulfill the social responsibility of listed companies, the company decided to donate 50 million yuan worth of continuous flowers to Shanghai through the Red Cross Foundation of China. Qingwen epidemic prevention materials. Previously, the company has donated Lianhua Qingwen capsules worth 11 million yuan to Shanghai through the Chinese Red Cross Foundation and the Shanghai Red Cross Society. This is the second batch of donations urgently needed for local epidemic prevention and control. "
Wang Sicong's investment company moves frequently
According to public information, Wang Sicong is the only son of Wang Jianlin, chairman of Wanda Group. He graduated from the Department of Philosophy at University College London, chairman of Beijing Pusi Investment Co., Ltd., founder of IG e-sports club, and director of Wanda Group.
According to Tianyancha information, Wang Sicong currently serves as the legal representative of 9 companies and a shareholder in 30 companies.
As a well-known Weibo V, Wang Sicong's every move has attracted the attention of the Internet.
Previously, Wang Sicong founded Shanghai Panda Mutual Entertainment Culture Co., Ltd. (hereinafter referred to as "Panda Mutual Entertainment").
Not long after, Panda Entertainment was listed as a dishonest and enforced enterprise by the court. Wang Sicong was also listed by the court as a person subject to enforcement many times and was restricted from high consumption. It was not until the end of 2019 that the consumption restriction order was successively lifted.
On December 26, 2019, Price Capital, a subsidiary of Wang Sicong, issued a statement stating that all investors of Panda Interactive Entertainment have been compensated, and the huge investment losses of Panda Interactive Entertainment of nearly 2 billion yuan are all borne by Price Investment and the actual controller.
In January 2020, Panda Interactive Entertainment entered the actual bankruptcy liquidation procedure.
In December last year, Wang Sicong was revealed that his company would be auctioned off with 11 million creditor's rights, which aroused heated discussions among netizens.
It is understood that the accounts receivable of Panda Interactive Entertainment was auctioned at a discount. The company was owed nearly 60 million yuan by more than 30 debtors and will be auctioned at a discount, with a total starting price of 11 million yuan.
According to the information from Tianyancha, Price Investment, which is wholly-owned by Wang Sicong, has also made frequent moves recently.
On January 30 this year, Price Investment invested in Jiuhuan Carbon Technology (Beijing) Co., Ltd. (hereinafter referred to as "Jiuhuan Carbon Structure").
Tianyancha shows that Jiuhuan Carbon Group was established on January 28, 2022 with a registered capital of 80 million yuan. Its business scope includes: natural scientific research and experimental development, engineering and technology research and experimental development, electronic special material manufacturing, semiconductor devices Special equipment manufacturing.
It is reported that this is the first time that Price Investment has set foot in the semiconductor field.
On September 8, 2021, Price Investment also invested in Suzhou Tidu Education Technology Co., Ltd.
Titan Education was established in September 2017. It is an e-sports education and training enterprise. Titan Education was founded by the former Warcraft famous professional player Li Xiaofeng (Human Emperor Sky). It mainly provides e-sports vocational education and training, joint school running, Talent service, school-enterprise cooperation, etc.
According to the official website of Price Capital, Price Capital is an investment institution focusing on investing in early and growth-stage opportunities in the Internet, technology, and consumer fields.
Its funds have invested in nearly 80 high-quality projects, including Meituan, Dewu, Flash Delivery, Ferris Wheel, Dolphin Home, Lele Tea, Palantir, Magic Leap, Gusto, Amethyst Storage, etc.
As of June 2020, the fund has completed the exit of more than 30 projects.
( Brokerage China )